Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
6 papers
This review examines studies on how testosterone relates to anxiety and depression and how that might help explain sex differences in these disorders. About 18% of U.S. adults have an anxiety disorder each year and about 7% have major depressive disorder, and women are more than twice as likely as…
This review says sexual problems are common side effects of many antidepressant medicines. The exact chance varies a lot between studies. Problems can include lower sex drive, less excitement, delayed or lost orgasms, and erection or ejaculation trouble. Some drugs (many SSRIs and venlafaxine) often show high rates, while others…
This paper combined past studies (a meta-analysis) and a genetic test (Mendelian randomization) to look at blood testosterone and depression in women. The meta-analysis found that women with depression have significantly different serum testosterone levels than healthy women, with a clear result in premenopausal women and weaker (borderline) results in…
This study asked 452 outpatients in Türkiye who had used one antidepressant for at least one month about sexual problems. Using a standard questionnaire, researchers found very high rates of self-reported sexual dysfunction: 88.7% of women and 84.5% of men. Women taking bupropion reported lower levels of sexual dysfunction than…
Post-SSRI sexual dysfunction (PSSD) is a condition where sexual problems start with SSRIs or related antidepressants and keep going after the medicine is stopped. Common symptoms are genital numbness, weak or pleasureless orgasms, low libido, and erectile problems. Researchers say we do not know how common PSSD is because studies…
The Scott Trust, Guardian Media Group (GMG) and The Scott Trust Endowment Limited (STEL) published a modern slavery statement for the year ending 31 March 2025. It says they use policies, supplier checks, contract clauses, training and investment oversight to try to lower the risk of modern slavery in their…
